Study: New class of oncology therapies provides more options, better outcomes

Monday, June 5, 2017

During the past decade, advances in personalized medicine and immuno-oncology have fueled a major shift in treatment of cancer, according to new research from the QuintilesIMS Institute. Since 2011, 68 novel therapies have been approved across 22 cancer indications globally. These developments have led to more options as well as greater access and improved outcomes for patients—especially for those individuals with metastatic disease.

[Read More]

Report: Spending on medicines totaled $450B in 2016

Thursday, May 4, 2017

In a QuintilesIMS report, various aspects of the market for medicines in the U.S. is highlighed—panning aggregate spending, key medicine categories, volumes, patient cost exposure, as well as an outlook to 2021. The report seeks to provide appropriate context and perspective around the complex factors that drive the level of spending on medicines and their role in our healthcare system.

[Read More]

Domestic Research Enhancement Act of 2017 endorsed by many

Tuesday, April 11, 2017

The Domestic Research Enhancement Act of 2017 (H.R. 1234), which modernizes the R&D tax credit to recognize the essential role contract research now plays in the development of new pharmaceuticals, biologics and medical devices, has been introduced by Rep. Pat Meehan (R-PA) and co-sponsors Rep. George Holding (R-NC) and G.K. Butterfield (D-NC).

[Read More]

Reassessing site engagement activities

Wednesday, February 1, 2017

Drug development sponsors and CROs increasingly recognize the importance of investigative sites having a stronger, more respected voice in the clinical research community and have begun adopting initiatives designed to incorporate site viewpoints into improving clinical development processes.

[Read More]

Report: Global drug market will hit $1.5T in 2021

Friday, December 9, 2016

Total spending on medicines is forecast to reach $1.5 trillion by 2021, up 33% from 2016 levels, even as annual growth moderates from the record pace set in 2014 and 2015, according to new research released by the QuintilesIMS Institute. While historically large numbers of high-quality new medicines will emerge from the R&D pipeline in the next five years, pricing and market access pressures, lower volume growth in pharmerging markets and greater savings from patent expiries will contribute to the lower rate of growth.

[Read More]